Form 4 for LFCR LIFECORE BIOMEDICAL, INC. DE
Accepted 2023-06-05 00:00:00 ET · period of report 2023-06-01 · accession 0001628280-23-020843 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-05 | 2023-06-01 | LFCR | Diradoorian Raymond H | Dir | A - Grant | — | +18.2K | 30.4K | +149% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-01 | A | A | 18,182 | — | 30,424 | D | — | — | (F2) Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date). (F1) The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. |